Compare PLSE & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | INNV |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2015 | 2021 |
| Metric | PLSE | INNV |
|---|---|---|
| Price | $25.47 | $7.23 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 1 | 1 |
| Target Price | ★ $22.00 | $7.00 |
| AVG Volume (30 Days) | ★ 328.8K | 226.6K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $853,699,000.00 |
| Revenue This Year | $840.00 | $12.85 |
| Revenue Next Year | $287.54 | $8.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.76 |
| 52 Week Low | $12.56 | $3.13 |
| 52 Week High | $27.98 | $10.69 |
| Indicator | PLSE | INNV |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 37.89 |
| Support Level | $17.58 | $7.00 |
| Resistance Level | $26.30 | $8.61 |
| Average True Range (ATR) | 1.75 | 0.41 |
| MACD | 0.56 | -0.08 |
| Stochastic Oscillator | 69.75 | 13.38 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.